Interactive Financial Charts Not Available

Sai Life Sciences (SAILIFE) | Financial Analysis & Statements

Sai Life Sciences Ltd. | Mid-cap | Healthcare

₹887.80

3.15%

Sai Life Sciences vs Dr. Lal PathLabs Sai Life Sciences vs Syngene Sai Life Sciences vs Metropolis Sai Life Sciences vs Vijaya Diagnostic Sai Life Sciences vs Thyrocare Sai Life Sciences vs NIFTY 50 | Market

TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 5.0B

Gross Profit 1.9B 39.22%

Operating Income 832.1M 16.76%

Net Income 604.6M 12.18%

EPS (Diluted) ₹2.83

Balance Sheet Metrics

Total Assets 31.6B

Total Liabilities 10.3B

Shareholders Equity 21.3B

Debt to Equity 0.48

Cash Flow Metrics

Revenue & Profitability Trend

Interactive Financial Charts Not Available

This page uses interactive financial charts and dynamic data visualization tools that require JavaScript. For detailed financial analysis:

Available Financial Data:

Income statements (annual and quarterly)
Balance sheets with asset and liability details
Cash flow statements and free cash flow analysis
Key financial ratios and performance metrics
Peer comparison and industry benchmarking

All financial data is displayed in accessible table format below. Use the table headers and structure to analyze trends and compare metrics across different periods.

Sai Life Sciences Income Statement From 2022 to 2025

Metric	2025	2024	2023	2022
Revenue i	16.6B	14.7B	12.0B	8.7B
Cost of Goods Sold i	10.4B	4.5B	4.6B	2.9B
Gross Profit i	6.2B	10.2B	7.4B	5.8B
Gross Margin % i	37.3%	69.6%	61.4%	66.3%
Operating Expenses
Research & Development i	-	-	-	-
Selling, General & Administrative i	469.3M	474.5M	311.5M	339.7M
Other Operating Expenses i	1.7B	2.4B	1.3B	1.1B
Total Operating Expenses i	2.2B	2.9B	1.6B	1.4B
Operating Income i	2.7B	1.7B	768.3M	354.7M
Operating Margin % i	16.5%	11.3%	6.4%	4.1%
Non-Operating Items
Interest Income i	175.6M	136.0M	106.6M	70.5M
Interest Expense i	761.6M	859.1M	770.6M	495.7M
Other Non-Operating Income	-	-	-	-
Pre-tax Income i	2.3B	1.1B	164.1M	97.0M
Income Tax i	575.7M	264.2M	64.2M	34.7M
Effective Tax Rate % i	25.3%	24.2%	39.1%	35.8%
Net Income i	1.7B	828.1M	99.9M	62.3M
Net Margin % i	10.2%	5.7%	0.8%	0.7%
Key Metrics
EBITDA i	4.5B	3.1B	2.0B	1.4B
EPS (Basic) i	₹8.83	₹3.98	₹0.48	₹0.30
EPS (Diluted) i	₹8.61	₹3.98	₹0.48	₹0.30
Basic Shares Outstanding i	192633970	207989529	207989529	207989529
Diluted Shares Outstanding i	192633970	207989529	207989529	207989529

Income Statement Trend

Sai Life Sciences Balance Sheet From 2022 to 2025

Metric	2025	2024	2023	2022
Assets
Current Assets
Cash & Equivalents i	911.2M	236.6M	699.1M	1.2B
Short-term Investments i	2.8B	1.6B	1.4B	1.0B
Accounts Receivable i	3.5B	2.6B	2.8B	2.4B
Inventory i	1.2B	874.4M	1.4B	1.3B
Other Current Assets	4.9B	-	-	-
Total Current Assets i	15.0B	9.5B	9.6B	9.5B
Non-Current Assets
Property, Plant & Equipment i	1.5B	0	0	0
Goodwill i	108.6M	137.7M	114.3M	80.5M
Intangible Assets i	108.6M	137.7M	114.3M	80.5M
Long-term Investments	-	0	2.2M	0
Other Non-Current Assets	131.1M	-	-	-
Total Non-Current Assets i	16.6B	13.3B	12.2B	12.2B
Total Assets i	31.6B	22.8B	21.9B	21.6B
Liabilities
Current Liabilities
Accounts Payable i	3.2B	2.0B	2.1B	2.0B
Short-term Debt i	1.9B	4.7B	4.8B	4.8B
Current Portion of Long-term Debt	-	-	-	-
Other Current Liabilities	1.3B	-	-	-
Total Current Liabilities i	7.3B	7.4B	7.6B	7.1B
Non-Current Liabilities
Long-term Debt i	1.6B	4.5B	4.6B	4.9B
Deferred Tax Liabilities i	1.1B	862.7M	625.3M	626.0M
Other Non-Current Liabilities	-10.0K	-	-	-
Total Non-Current Liabilities i	3.0B	5.6B	5.4B	5.7B
Total Liabilities i	10.3B	13.0B	13.0B	12.9B
Equity
Common Stock i	208.4M	176.6M	176.2M	175.6M
Retained Earnings i	7.2B	5.5B	4.7B	4.6B
Treasury Stock i	-	-	-	-
Other Equity	-	-	-	-
Total Shareholders Equity i	21.3B	9.8B	8.9B	8.8B
Key Metrics
Total Debt i	3.5B	9.3B	9.3B	9.7B
Working Capital i	7.7B	2.1B	2.1B	2.3B

Balance Sheet Composition

Sai Life Sciences Cash Flow Statement From 2022 to 2025

Metric	2025	2024	2023	2022
Operating Activities
Net Income i	2.3B	1.1B	164.1M	97.0M
Depreciation & Amortization i	-	-	-	-
Stock-Based Compensation i	24.8M	22.5M	8.1M	22.4M
Working Capital Changes i	-2.4B	318.1M	225.4M	-888.5M
Operating Cash Flow i	518.1M	2.2B	1.1B	-343.9M
Investing Activities
Capital Expenditures i	-3.7B	-1.8B	-711.7M	-1.1B
Acquisitions i	-750.0K	0	-	-
Investment Purchases i	-	-1.2B	-39.2M	-46.9M
Investment Sales i	-	-	-	-
Investing Cash Flow i	-3.7B	-2.0B	-1.1B	-1.1B
Financing Activities
Share Repurchases i	-	-	-	-
Dividends Paid i	-	-	-	-
Debt Issuance i	534.1M	750.0M	300.0M	1.0B
Debt Repayment i	-3.9B	-667.3M	-532.8M	-316.2M
Financing Cash Flow i	4.4B	341.3M	-876.2M	1.5B
Free Cash Flow i	-552.4M	814.0M	1.1B	-1.0B
Net Change in Cash i	1.2B	451.8M	-915.6M	-13.7M

Cash Flow Trend

Sai Life Sciences Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 73.75

Forward P/E 52.85

Price to Book 8.42

Price to Sales 9.43

Profitability Ratios

Profit Margin 12.77%

Operating Margin 16.76%

Return on Equity 7.99%

Return on Assets 5.38%

Financial Health

Current Ratio 2.05

Debt to Equity 16.56

Per Share Data

EPS (TTM) ₹11.67

Book Value per Share ₹102.24

Revenue per Share ₹95.95

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
sailife	180.3B	73.75	8.42	7.99%	12.77%	16.56
Dr. Lal PathLabs	265.3B	51.84	11.96	22.08%	20.29%	7.14
Syngene	250.3B	48.97	5.30	10.50%	13.61%	12.23
Metropolis	106.5B	69.23	7.92	10.86%	10.83%	15.30
Vijaya Diagnostic	104.8B	68.59	12.88	17.90%	21.04%	39.99
Thyrocare	65.0B	54.89	11.13	16.73%	14.69%	4.51

Financial data is updated regularly. All figures are in the company's reporting currency.